Search details
1.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36868112
2.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36706645
3.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol
; 175: 194, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37271667
4.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Cancer Med
; 13(9): e7168, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38733172
5.
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
Clin Cancer Res
; 2024 Apr 26.
Article
in English
| MEDLINE | ID: mdl-38669064
6.
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Sci Rep
; 13(1): 13427, 2023 08 18.
Article
in English
| MEDLINE | ID: mdl-37596388
7.
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
Eur J Cancer
; 174: 221-231, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36067615
8.
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Clin Pharmacol Ther
; 109(5): 1244-1255, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33047329
9.
[Breast cancer in young women. Histological and prognostic specificities: how are they different from older women?] / Cancer du sein de la femme jeune. Spécificités histologiques, pronostiques : en quoi sont-elles différentes des femmes plus âgées ?
Bull Cancer
; 106(12S1): S10-S18, 2019 Dec.
Article
in French
| MEDLINE | ID: mdl-32008732
10.
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
Eur J Cancer
; 122: 91-100, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31634648
11.
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]. / Attentes des patientes suivies pour un cancer de l'ovaire concernant les traitements d'entretien : résultats de la cohorte française GINECO de l'enquête européenne NOGGO/ENGOT-ov22 (Expression IV).
Bull Cancer
; 105(5): 465-474, 2018 May.
Article
in French
| MEDLINE | ID: mdl-29544693
12.
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
PLoS One
; 12(5): e0175998, 2017.
Article
in English
| MEDLINE | ID: mdl-28481884
13.
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)]. / COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d'Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG).
Bull Cancer
; 107(5): 528-537, 2020 05.
Article
in French
| MEDLINE | ID: mdl-32278467
14.
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]. / Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux: une approche pragmatique.
Bull Cancer
; 98(7): 807-25, 2011 Jul.
Article
in French
| MEDLINE | ID: mdl-21727059
15.
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
J Thorac Oncol
; 3(8): 894-901, 2008 Aug.
Article
in English
| MEDLINE | ID: mdl-18670308
Results
1 -
15
de 15
1
Next >
>>